Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Saving of U.S. costs through generic pharmaceuticals by therapy 2017

Cost savings through generics in the United States in 2017, by therapeutic area (in billion U.S. dollars)*

by Matej Mikulic, last edited Jul 17, 2018
Saving of U.S. costs through generic pharmaceuticals by therapy 2017 This statistic displays the cost savings in the United States associated with using generic pharmaceuticals in 2017, by therapeutic area. In that year, 16 billion U.S. dollars were saved due to generics in the nervous system disorders area. Over the last decade, an estimated 1.67 trillion U.S. dollars were saved through the use of generic pharmaceuticals in the United States.
Cost savings through generics

In 2017, generics targeting mental health and cholesterol therapies have created the greatest amount of cost savings in the U.S., totaling 42 and 32 billion U.S. dollars, respectively. Teva and Mylan have garnered the largest revenues of the generics market worldwide in 2016, accumulating nearly 10 billion dollars each. For example, Teva produces both the branded and generic form of Adderall, a medication used to target attention deficit hyperactivity disorder and narcolepsy.

Generic products are increasingly becoming an economically and medically sound alternative to branded products. These products are usually sold for a much lower price than branded drugs; this is due to expiry of patents which raises competition in the industry. Generic products contain the same active ingredients found in branded pharmaceutical products. Abilify (or aripiprazole) was among one of the many drugs that went generic until 2016, it retains revenue of 4.9 billion U.S. dollars annually. Generic drug products can also feed off of past advertisements and marketing efforts for the branded product.
Show more

Cost savings through generics in the United States in 2017, by therapeutic area (in billion U.S. dollars)*

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Generics and biosimilars
Generics and biosimilars

All Information
in one Presentation

Generics and biosimilars

Everything On "Generics and biosimilars" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Generics and biosimilars"
  • Global overview
  • Top companies
  • U.S. market
  • Patent expiration
  • Savings
The most important statistics
  • Biosimilars
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.